THE EMORY HEALTHY BRAIN STUDY: DISCOVERING PREDICTIVE BIOMARKERS FOR ALZHEIMER'S DISEASE - ABSTRACT/SUMMARY PROGRESS IN UNDERSTANDING ALZHEIMER’S DISEASE AND RELATED DISORDERS (ADRD) IS CLOSE TO PRODUCING MORE EFFECTIVE TREATMENTS, CREATING AN URGENT NEED FOR DISEASE-PREDICTIVE BIOMARKERS TO GUIDE THEIR USE. USING CEREBROSPINAL FLUID (CSF) MEASUREMENTS OF BETA-AMYLOID AND TAU AND POSITRON-EMISSION TOMOGRAPHY TRACERS, WE CAN DETECT AD PATHOLOGY IN COGNITIVELY NORMAL INDIVIDUALS. HOWEVER, CURRENT TOOLS DO NOT ALLOW US TO PREDICT WHEN OR EVEN IF AN INDIVIDUAL WITH ASYMPTOMATIC PATHOLOGY WILL DEVELOP SYMPTOMS. TO ADDRESS THIS NEED, WE PROPOSE TO LONGITUDINALLY STUDY =3000 COGNITIVELY NORMAL INDIVIDUALS (50-75 YEARS AT ENROLLMENT) IN THE EMORY HEALTHY BRAIN STUDY TO DEFINE THE FREQUENCY OF ASYMPTOMATIC AD AND RATES OF COGNITIVE DECLINE IN A RACIALLY DIVERSE COHORT OF HEALTHY INDIVIDUALS (SPECIFIC AIM 1). AN IMPORTANT GOAL OF AIM 1 IS TO ACHIEVE =33% AFRICAN- AMERICAN PARTICIPANTS TO PROVIDE

Summary

THE EMORY HEALTHY BRAIN STUDY: DISCOVERING PREDICTIVE BIOMARKERS FOR ALZHEIMER'S DISEASE - ABSTRACT/SUMMARY PROGRESS IN UNDERSTANDING ALZHEIMER’S DISEASE AND RELATED DISORDERS (ADRD) IS CLOSE TO PRODUCING MORE EFFECTIVE TREATMENTS, CREATING AN URGENT NEED FOR DISEASE-PREDICTIVE BIOMARKERS TO GUIDE THEIR USE. USING CEREBROSPINAL FLUID (CSF) MEASUREMENTS OF BETA-AMYLOID AND TAU AND POSITRON-EMISSION TOMOGRAPHY TRACERS, WE CAN DETECT AD PATHOLOGY IN COGNITIVELY NORMAL INDIVIDUALS. HOWEVER, CURRENT TOOLS DO NOT ALLOW US TO PREDICT WHEN OR EVEN IF AN INDIVIDUAL WITH ASYMPTOMATIC PATHOLOGY WILL DEVELOP SYMPTOMS. TO ADDRESS THIS NEED, WE PROPOSE TO LONGITUDINALLY STUDY =3000 COGNITIVELY NORMAL INDIVIDUALS (50-75 YEARS AT ENROLLMENT) IN THE EMORY HEALTHY BRAIN STUDY TO DEFINE THE FREQUENCY OF ASYMPTOMATIC AD AND RATES OF COGNITIVE DECLINE IN A RACIALLY DIVERSE COHORT OF HEALTHY INDIVIDUALS (SPECIFIC AIM 1). AN IMPORTANT GOAL OF AIM 1 IS TO ACHIEVE =33% AFRICAN- AMERICAN PARTICIPANTS TO PROVIDE